Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Hydroxycamptothecin

Hydroxycamptothecin

pharmaceutical raw materials
Hydroxycamptothecin structure

Hydroxycamptothecin 

structure
  • CAS No:

    19685-09-7

  • Formula:

    C20H16N2O5

  • Chemical Name:

    Hydroxycamptothecin

  • Synonyms:

    1H-Pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,4-ethyl-4,9-dihydroxy-,(4S)-;Camptothecine,10-hydroxy-;1H-Pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione,4-ethyl-4,9-dihydroxy-,(S)-;(4S)-4-Ethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;10-Hydroxycamptothecine;Hydroxycamptothecin;10-Hydroxycamptothecin;(S)-10-Hydroxycamptothecin;NSC 107124;(+)-10-Hydroxycamptothecin;ChEMBL 273862;10-HCPT;104155-90-0;157405-42-0

  • Categories:

    Active Pharmaceutical Ingredients  >  Antineoplastic Agents

Description

(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.IC50 value:Target:In vitro: In vitro, the 10-hydroxycamptothecin nanosuspensions released the encapsulated drug with nearly zero-order kinetics, and the accumulative release reached 90% within 72 hours. In vitro cytotoxicity assay showed that the 10-hydroxycamptothecin nanosuspensions had significantly enhanced cytotoxicity against HepG2 cells compared to the commercially available 10-hydroxycamptothecin injections [


10-Hydroxycamptothecin is a pyranoindolizinoquinoline.|10-hydroxycamptothecin is under investigation in clinical trial NCT00956787 (Study of AR-67 (DB-67) in Myelodysplastic Syndrome (MDS)).

Hydroxycamptothecin Basic Attributes

364.35

364.35

2017-001-1

9Z01632KRV

107124

2934999090

Characteristics

100

1.32

1.6±0.1 g/cm3

268-270 °C @ Solvent: Chloroform, Methanol, Ethyl acetate

820.7°C at 760 mmHg

450.1±34.3 °C

1.777

-20°C Freezer

187 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

Safety Information

NONH for all modes of transport

24/25

P201, P202, P260, P264, P270, P273, P281, P308+P313, P314, P405, P501

H340

|Danger|H301+H311+H331 (50%): Toxic if swallowed, in contact with skin or if inhaled [Danger Acute toxicity, oral; acute toxicity, dermal; acute toxicity, inhalation]|P201, P202, P260, P261, P264, P270, P271, P273, P280, P281, P301+P310, P302+P352, P304+P340, P308+P313, P311, P312, P314, P321, P322, P330, P361, P363, P403+P233, P405, and P501|Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Drug Information

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (See all compounds classified as Antineoplastic Agents, Phytogenic.)

10-hydroxycamptothecin

Hydroxycamptothecin Use and Manufacturing

A Camptothecin derivative; a topoisomerase inhibitor for cancer therapy

Computed Properties

Molecular Weight:364.4
XLogP3:0.6
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:6
Rotatable Bond Count:1
Exact Mass:364.10592162
Monoisotopic Mass:364.10592162
Topological Polar Surface Area:100
Heavy Atom Count:27
Complexity:774
Defined Atom Stereocenter Count:1
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Recommended Suppliers of Hydroxycamptothecin

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.